Buy-Side Firms Deploy AI for Productivity, Not Alpha, Risk.net Survey Finds
Buy-side quantitative firms have moved AI from experimentation into production, but only 13% describe their deployment as enterprise-wide, according to a white paper based on a global survey of 68 buy-side professionals published by Risk.net.
The survey found 33% of firms report limited production use of AI, while 28% have multiple production use cases. Firms remain focused on applications that deliver measurable productivity gains rather than replacing established investment processes.
At 82%, information search and retrieval tops the list of use cases among respondents, with document and text summarisation close behind at 74%. Coding also delivers value, helping investment professionals process large volumes of unstructured information and reduce manual workloads.
Rather than displacing investment professionals, AI is enhancing their work: firms’ first applications target information-heavy workflows, not core investment decisions. That caution reflects a confidence gap — 59% cite hallucinations or inaccurate outputs as a major obstacle, ahead of compliance and auditability at 40%. Human oversight remains central, with people involved in reviewing or validating NLP and LLM outputs more than 90% of the time.

On the value question, the survey draws a clear dividing line: 57% of respondents see large language models becoming an important productivity tool, compared with 24% who see potential for competitive advantage.
In terms of architecture, firms have adopted a pragmatic stance, mixing commercial and proprietary models with traditional NLP, prompt engineering and newer approaches such as retrieval-augmented generation.
The productivity-over-alpha split frames the technology’s current standing: most firms trust AI to make their existing work faster, far fewer expect it to give them an edge over rivals.
Keep reading
- UKEF Issues Letter of Interest for Up to C$220 Million Loan to First Phosphate
- Anthropic Sets IPO Price at $83 Per Share Ahead of Nasdaq Debut
- Study: Omalizumab May Reduce Alpha-Gal Allergy Severity (newsy-today.com)
- Median Net Worth Peaks at 75+ in the Fed's Survey, but the Lead Is Thin (daybreakwire.com)